EC
GPCR icon

EntryPoint Capital’s Structure Therapeutics GPCR Stock Holding History

EntryPoint Capital’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,260
Closed -$360K – 775
2024
Q4 		$360K Buy
13,260
+8,095
+157% +$287K 0.15% 258
2024
Q3 		$227K Buy
5,165
+1,480
+40% +$57.2K 0.13% 386
2024
Q2 		$145K Buy
3,685
+3,467
+1,590% +$142K 0.21% 136
2024
Q1 		$9.34K Sell
218
-7,617
-97% -$321K 0.01% 1245
2023
Q4 		$319K Buy
+7,835
New +$449K 0.31% 18

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

EntryPoint Capital's GPCR Position: Q1 2025 in Review

EntryPoint Capital sold out of Structure Therapeutics (GPCR) in Q1 2025, closing a stake of 13,260 shares — an estimated $360K sold.

EntryPoint Capital first reported a position in GPCR in Q4 2023 and held it in 5 quarters. The position peaked at $360K in Q4 2024. 150 funds tracked by Wall St. Rank hold GPCR as of Q1 2025.

  • EntryPoint Capital reported no remaining Structure Therapeutics position as of Q1 2025 after selling out during the quarter.
  • EntryPoint Capital sold 13,260 Structure Therapeutics shares in Q1 2025, an estimated $360K.
  • EntryPoint Capital first reported a position in Structure Therapeutics in Q4 2023 and held it in 5 quarters.
  • EntryPoint Capital's Structure Therapeutics position peaked at $360K in Q4 2024.
  • 150 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2025.

Based on EntryPoint Capital's 13F filing for Q1 2025, filed 14 May 2025.